These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 16940118)

  • 1. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin.
    Stevens DA; Ichinomiya M; Koshi Y; Horiuchi H
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3160-1. PubMed ID: 16940118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence.
    Rueda C; Cuenca-Estrella M; Zaragoza O
    Antimicrob Agents Chemother; 2014; 58(2):1071-83. PubMed ID: 24295973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Paradoxical Effect of Echinocandins in Aspergillus fumigatus Relies on Recovery of the β-1,3-Glucan Synthase Fks1.
    Loiko V; Wagener J
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerance to Caspofungin in Candida albicans Is Associated with at Least Three Distinctive Mechanisms That Govern Expression of
    Yang F; Zhang L; Wakabayashi H; Myers J; Jiang Y; Cao Y; Jimenez-Ortigosa C; Perlin DS; Rustchenko E
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Candida albicans strain with high MIC for caspofungin and no FKS1 mutations exhibits a high chitin content and mutations in two chitinase genes.
    Drakulovski P; Dunyach C; Bertout S; Reynes J; Mallié M
    Med Mycol; 2011 Jul; 49(5):467-74. PubMed ID: 21108572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoscale effects of caspofungin against two yeast species, Saccharomyces cerevisiae and Candida albicans.
    Formosa C; Schiavone M; Martin-Yken H; François JM; Duval RE; Dague E
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3498-506. PubMed ID: 23669379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caspofungin-induced β(1,3)-glucan exposure in
    Wagner AS; Lumsdaine SW; Mangrum MM; Reynolds TB
    mBio; 2023 Aug; 14(4):e0007423. PubMed ID: 37377417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reshuffling of Aspergillus fumigatus cell wall components chitin and β-glucan under the influence of caspofungin or nikkomycin Z alone or in combination.
    Verwer PE; van Duijn ML; Tavakol M; Bakker-Woudenberg IA; van de Sande WW
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1595-8. PubMed ID: 22203603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture.
    Kahn JN; Hsu MJ; Racine F; Giacobbe R; Motyl M
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2214-6. PubMed ID: 16723587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of a high affinity fibronectin receptor in Candida albicans by caspofungin: requirements for beta (1,6) glucans and the developmental regulator Hbr1p.
    Pendrak ML; Rodrigues RG; Roberts DD
    Med Mycol; 2007 Mar; 45(2):157-68. PubMed ID: 17365652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species.
    Bizerra FC; Melo AS; Katchburian E; Freymüller E; Straus AH; Takahashi HK; Colombo AL
    Antimicrob Agents Chemother; 2011 Jan; 55(1):302-10. PubMed ID: 21060107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoscopic cell-wall architecture of an immunogenic ligand in Candida albicans during antifungal drug treatment.
    Lin J; Wester MJ; Graus MS; Lidke KA; Neumann AK
    Mol Biol Cell; 2016 Mar; 27(6):1002-14. PubMed ID: 26792838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments.
    Clancy CJ; Huang H; Cheng S; Derendorf H; Nguyen MH
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2569-72. PubMed ID: 16801448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucan-associated protein modulations and ultrastructural changes of the cell wall in Candida albicans treated with micafungin, a water-soluble, lipopeptide antimycotic.
    Angiolella L; Maras B; Stringaro AR; Arancia G; Mondello F; Girolamo A; Palamara AT; Cassone A
    J Chemother; 2005 Aug; 17(4):409-16. PubMed ID: 16167521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.
    Stevens DA; Espiritu M; Parmar R
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3407-11. PubMed ID: 15328104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of the paradoxical effect of caspofungin at high drug concentrations.
    Stevens DA; White TC; Perlin DS; Selitrennikoff CP
    Diagn Microbiol Infect Dis; 2005 Mar; 51(3):173-8. PubMed ID: 15766602
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Lee HS; Kim Y
    J Microbiol Biotechnol; 2020 Jul; 30(7):967-973. PubMed ID: 32347080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevation of cell wall chitin via Ca
    Han Q; Wang N; Pan C; Wang Y; Sang J
    Mol Microbiol; 2019 Sep; 112(3):960-972. PubMed ID: 31240791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways.
    Wiederhold NP; Kontoyiannis DP; Prince RA; Lewis RE
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5146-8. PubMed ID: 16304189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment.
    Wheeler RT; Kombe D; Agarwala SD; Fink GR
    PLoS Pathog; 2008 Dec; 4(12):e1000227. PubMed ID: 19057660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.